This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Medidata Solutions Announces Enhanced Capabilities And Stand-Alone Option For Medidata Balance

Medidata Solutions (NASDAQ: MDSO), a leading global provider of cloud-based clinical development solutions, announced that Medidata Balance , the intelligent randomization and trial supply solution, is now being offered as a stand-alone system. This is a new alternative to the Balance solution that is unified with Medidata Rave ®, the industry-leading electronic data capture (EDC), management and reporting system.

With powerful enhancements, including new trial supply capabilities and additional ways to conduct randomized trials, Balance introduces a new level of agility in randomization and supply management, whether used with or without Medidata Rave for electronic data collection.

As always, with Medidata Balance the need for software programming and extensive testing is eliminated. Balance brings together all elements of the design and execution of randomization and supply logistics plans into one simple solution operating out of the Medidata Clinical Cloud. The new version includes:
  • A straightforward web interface guiding the creation of the randomization design and supply plans, including definition of complex dosing rules,
  • A powerful dynamic allocation algorithm or permuted block method, now offering integrated list generation, that creates the assignments to arms and strata, and
  • A groundbreaking integrated simulation tool testing the allocation of subjects and confirming the desired level of balance.

The new stand-alone version uses the same clean interface to deliver randomization and supply logistical information to study site staff. Additionally, the cloud-based solution offers site users a simple, intuitive web interface for screening, enrollment, randomization and kit dispensation.

“We continue to enhance the power and versatility of Medidata Balance to enable our customers to be more agile – to quickly adapt to changing needs and priorities, manage increased trial complexity and realize new efficiencies,” said Glen de Vries, president, Medidata Solutions. “With the introduction of this new version of Balance, customers can create and execute trial randomization and supply plans within the pre-validated solution and without being restricted by EDC compatibility.”

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.75 -1.10%
FB $117.53 0.69%
GOOG $693.00 0.29%
TSLA $240.75 -2.80%
YHOO $36.61 0.06%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs